Search results
Results from the WOW.Com Content Network
Serious side effects may include anaphylaxis, liver problems, depression, and muscle breakdown. [4] [5] Use in pregnancy and breastfeeding is of unclear safety. [10] Ezetimibe works by decreasing cholesterol absorption in the intestines. [5] Ezetimibe was approved for medical use in the United States in 2002. [4] It is available as a generic ...
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]
Managing cholesterol at the site of absorption is an increasingly popular strategy in the treatment of hypercholesterolemia [citation needed].Cholesterol absorption inhibitors are known to have a synergistic effect when combined a class of antihyperlipidemics called statins, to achieve an overall serum cholesterol target.
Bempedoic acid/ezetimibe, sold under the brand name Nexlizet among others, is a fixed-dose combination medication used for the treatment of high cholesterol. [1] [3] It is a combination of bempedoic acid and ezetimibe. [1] [2] The most common side effects are hyperuricemia (high blood levels of uric acid) and constipation. [2]
6 Potential Long-Term Effects of Ozempic. You may have heard about — or maybe even experienced — the short-term side effects of Ozempic® — such as nausea, vomiting, constipation, and diarrhea.
It is a combination of ezetimibe (known as Zetia in the United States) and the statin drug simvastatin (known as Zocor in the US). Ezetimibe reduces blood cholesterol by acting at the brush border of the small intestine and inhibiting the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver.
On average, statins can lower LDL cholesterol by 1.8 mmol/L (70 mg/dL), which translates into an estimated 60% decrease in the number of cardiac events (heart attack, sudden cardiac death) and a 17% reduced risk of stroke after long-term treatment. [36] A greater benefit is observed with high-intensity statin therapy. [37]
In a randomized study it showed a LDL-C reduction of 63.6 percent, significantly more than bempedoic acid/ezetimibe, and it may also be more effective than bempedoic acid / statin combination therapy.